Bevacizumab treatment before resection of colorectal liver metastases: Safety, recovery of liver function, pathologic assesment

Pathology and Oncology Research

Volumn 19, Issue 3, 2013, Pages 501-508

  Dede, K ^a   Mersich, T ^a   Besznyak I ^a   Zarand A ^b   Salamon, F ^a   Baranyai, Zs ^c   Landherr, L ^a   Jakab, F ^a   Bursics, A ^a  

^a UZSOKI HOSPITAL   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c Szent Imre Hospital   (Hungary)

Author keywords

Bevacizumab; Colorectal liver metastases; Complications; Functional liver recovery; Preoperative chemotherapy

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ALANINE AMINOTRANSFERASE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; CAMPTOTHECIN; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER MORTALITY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HEPATOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERNATIONAL NORMALIZED RATIO; LENGTH OF STAY; LIVER FUNCTION; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OPERATION DURATION; OUTCOME ASSESSMENT; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR NECROSIS; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; BLOOD; COLORECTAL NEOPLASMS; CYTOCHEMISTRY; ENZYMOLOGY; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; SECONDARY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ANALYSIS OF VARIANCE; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARTATE AMINOTRANSFERASES; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HISTOCYTOCHEMISTRY; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 84880328603     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-013-9608-2     Document Type: Article

References (31)

1. Adam R, Delvart V, Pascal G, et al. (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240:644-657
2. Kesmodel B, Ellis L, et al. (2008) Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 26(32):5224-5260
3. Wicherts DA, de Haas RJ, Adam R, et al. (2011) Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases. Br J Surg 98(3):399-407
4. Folprecht G, Gruenberger T, Bechstein WO, et al. (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11(1):38-47
5. Van Cutsem E, Rivera F, Berry S, et al. (2009) Safety and efficacy of firstline bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20(11):1842-1847
6. Scoggins CR, Campbell ML, Landry CS, et al. (2009) Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. Ann Surg Oncol 16(1):35-41
7. Vauthey JN, Pawlik TM, Ribero D, et al. (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24(13):2065-2072
8. Ribero D, Wang H, Donadon M, et al. (2007) Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110(12):2761-2767
9. Klinger M, Eipeldauer S, Hacker S, et al. (2009) Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 35(5):515-520
10. D'Angelica M, Kornprat P, Gonen M, et al. (2007) Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched casecontrol study. An Surg Oncol 14:759-765
11. Ellis LM, Curley SA, et al. (2005) Surgical resection after downsizing of colorectal liver metastasis in the era of Bevacizumab. J Clin Oncol 23(22):4853-4855
12. Reddy SK, Morse MA, Hurwitz HI, et al. (2008) Addition of bevacizumab to irinotecan and oxaliplatin based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 206:96-106
13. Mahfud M, Breitenstein S, El-Badry AM, et al. (2010) Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study. World J Surg 34(1):92-100
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. (2000) New guidelines to evaluate the response to treatment is solid tumors. J Natl Cancer Inst 92:205-216
15. Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205-213
16. Dan G, Blazer III, Kishi Y, et al. (2008) Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 25(33):5344-5351
17. Nordlinger B, Vauthey J-N, Poston G, et al. (2010) The timing of chemotherapy and surgery for the treatment of colorectal liver metastases. Clin Colorectal Cancer 9(4):212-218
18. Spelt L, Andersson B, Nilsson J, Andersson R (2012) Prognostic models for outcome following liver resection for colorectal cancer metastases: a systematic review. EJSO 38:16-24
19. Gruenberger B, Tamandl D, Schueller J, et al. (2008) Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26(11):1830-1835
20. Nordlinger B, Sorbye H, Glimelius B, et al. (2008) Perioperative chemotherapywith FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomisedcontrolled trial. Lancet 371(9617):1007-1016
21. Chua TC, Saxena A, Liauw A, et al. (2010) Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol 17(2):492-501
22. Nordlinger B, Van Cutsem E, Gruenberger T, European Colorectal Metastases Treatment Group; Sixth International Colorectal Liver Metastases Workshop, et al. (2009) Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 20(6):985-992
23. Lehmann K, Rickenbacher A, Weber A, Pestalozzi BC, Clavien PA (2012) Chemotherapy before liver resection of colorectal metastases: friend or foe? Ann Surg 255:237-247
24. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. (2005) Surgical woundhealing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91:173-180
25. Tamandl D, Gruenberger B, Klinger M, et al. (2010) Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study. Ann Surg 252(1):124-130
26. Kishi Y, Zorzi D, Contreras CM, et al. (2010) Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 17(11):2870-2876
27. Gordon MS, Margolin K, Talpaz M, et al. (2001) Phase I safety and pharmacokineticstudy of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19(3):843-850
28. Chun YS, Vauthey JN, Boonsirikamchai P, et al. (2009) Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal livermetastases. JAMA 302(21):2338-2344
29. Rubbia-Brandt L, Giostra E, Brezault C, et al. (2007) Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by liver surgery. Ann Oncol 18:299-304
30. Dipen MM, Kopetz S, Boonsirikamchai P, et al. (2010) Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol 34:1287-1294
31. Li Chang HH, Leeper WR, Chan G, Quan D, Driman DK (2012) Infarct-like necrosis. A distinct form of necrosis seen in colorectal carcinoma liver metastases treated with perioperative chemotherapy. Am J Surg Pathol 36:570-576